# Bioavailability and Practicability of Envarsus Versus Advagraf in Liver Transplant Recipients

> **NCT04720326** · PHASE4 · ACTIVE_NOT_RECRUITING · sponsor: **Edward Geissler** · enrollment: 268 (actual)

## Conditions studied

- Prophylaxis Against Liver Transplant Rejection

## Interventions

- **DRUG:** Tacrolimus Pill
- **DRUG:** Tacrolimus capsule

## Key facts

- **NCT ID:** NCT04720326
- **Lead sponsor:** Edward Geissler
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-12-23
- **Primary completion:** 2024-01-25
- **Final completion:** 2026-10
- **Target enrollment:** 268 (ACTUAL)
- **Last updated:** 2025-04-06

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04720326

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04720326, "Bioavailability and Practicability of Envarsus Versus Advagraf in Liver Transplant Recipients". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT04720326. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*